Rapt Therapeutics: Funding, Investors & Team (Sep 2026)
A clinical-stage biopharmaceutical business rooted on immunology, RAPT Therapeutics is dedicated to finding, developing, and commercializing oral small molecule treatments for people with serious unmet medical needs in oncology and inflammatory illnesses. The Company is creating highly specific small compounds to control the important immunological drivers underlying these diseases using its unique research and development engine. For the treatment of cancer and inflammation, respectively, RAPT has found and advanced two novel therapeutic candidates, FLX475 and RPT193, both of which target the C-C motif chemokine receptor 4 (CCR4). A variety of targets that are still in the discovery phase of development are also being pursued by the company.
Rapt Therapeutics has raised $471M across 3 funding rounds on record, the most recent an undisclosed round of $250M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rapt Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Rapt Therapeutics Funding Rounds
Rapt Therapeutics raised $70.5M in an undisclosed round announced in Nov 2022.
2.1 years later, an undisclosed round of $150M was announced in Dec 2024.
10 months later, an undisclosed round of $250M was announced in Oct 2025.
Rapt Therapeutics Founders and Leadership Team
Contact details for the Rapt Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Rapt Therapeutics Funding Compared to Other Biotechnology Startups
Rapt Therapeutics' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rapt Therapeutics in Biotechnology and South San Francisco
Companies Similar to Rapt Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Rapt Therapeutics Funding FAQs
What does Rapt Therapeutics do?
A clinical-stage biopharmaceutical business rooted on immunology, RAPT Therapeutics is dedicated to finding, developing, and commercializing oral small molecule treatments for people with serious unmet medical needs in oncology and inflammatory illnesses. The Company is creating highly specific small compounds to control the important immunological drivers underlying these diseases using its unique research and development engine. For the treatment of cancer and inflammation, respectively, RAPT has found and advanced two novel therapeutic candidates, FLX475 and RPT193, both of which target the C-C motif chemokine receptor 4 (CCR4). A variety of targets that are still in the discovery phase of development are also being pursued by the company.
How much funding has Rapt Therapeutics raised?
Rapt Therapeutics has raised $471M across 3 rounds on record. The most recent is an undisclosed round of $250M announced in Oct 2025.
When did Rapt Therapeutics last raise funding?
Rapt Therapeutics' most recent funding round on record is an undisclosed round of $250M, announced in Oct 2025.
Who founded Rapt Therapeutics?
FundedIQ lists Brian Wong (Founder) at Rapt Therapeutics.
Where is Rapt Therapeutics headquartered?
Rapt Therapeutics is based in South San Francisco, California, United States.
How many employees does Rapt Therapeutics have?
Rapt Therapeutics is in the 101-250 employee band.
How does Rapt Therapeutics' funding compare to other Biotechnology startups?
Rapt Therapeutics' latest round of $250M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Rapt Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rapt Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.